Serene
Active member
Exciting developments in cancer treatment! 
Researchers have identified a new type of tertiary lymphoid structure in liver tumors that may boost immunity and lower recurrence rates for hepatocellular carcinoma patients. 
Published in Nature Immunology, the study shows that tumors with these immune cell clusters respond better to treatment, resulting in reduced tumor size and a lower chance of recurrence.
Additionally, the FDA has approved lifileucel, a cellular therapy using tumor-infiltrating lymphocytes (TILs) to treat advanced melanoma, offering new hope for patients with solid tumors.
TILs are harvested from the patient's tumor, expanded, and then infused back into the body, enhanced with IL-2 for improved efficacy. While more research is needed, these breakthroughs are paving the way for more effective cancer treatments! 
Researchers have identified a new type of tertiary lymphoid structure in liver tumors that may boost immunity and lower recurrence rates for hepatocellular carcinoma patients. Published in Nature Immunology, the study shows that tumors with these immune cell clusters respond better to treatment, resulting in reduced tumor size and a lower chance of recurrence.Additionally, the FDA has approved lifileucel, a cellular therapy using tumor-infiltrating lymphocytes (TILs) to treat advanced melanoma, offering new hope for patients with solid tumors.
TILs are harvested from the patient's tumor, expanded, and then infused back into the body, enhanced with IL-2 for improved efficacy. While more research is needed, these breakthroughs are paving the way for more effective cancer treatments! 
